Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Toxicological Sciences

• Publication date

  2008-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2131/JTS.33.187PMID 18544910
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis between Clinical Efficacy of Salazosulfapyridine and Plasma Concentrations of Sulfapyridine in Patients with Rheumatoid Arthritis

  2007cited by this paper
• The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients.

  2006cited by this paper
• DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity.

  2006cited by this paper
• N-Acetyltransferase 2 Genotype-Related Efficacy of Sulfasalazine in Patients with Rheumatoid Arthritis

  2004cited by this paper
• CYP2E1 mediated isoniazid-induced hepatotoxicity in rats.

  2004cited by this paper
• Hepatic gene expression and lipid homeostasis in C57BL/6 mice exposed to hydrazine or acetylhydrazine.

  2004cited by this paper
• Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug‐induced hepatitis

  2003cited by this paper
• The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine

  2003cited by this paper
• Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients.

  2002cited by this paper
• Polymorphism of the N‐acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug–induced hepatitis

  2002cited by this paper
• GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a mini-HuGE review.

  2001cited by this paper
• Increased risk of antituberculosis drug‐induced hepatotoxicity in individuals with glutathione S‐transferase M1 ‘null’ mutation

  2001cited by this paper
• N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients.

  2001cited by this paper
• Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.

  2000cited by this paper
• Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor.

  1999cited by this paper
• Inhibition of Isoniazid-Induced Hepatotoxicity in Rabbits by Pretreatment with an Amidase Inhibitor 1 , 2

  1999cited by this paper
• Evidence on N-acetyltransferase allele-associated metabolism of hydrazine in Japanese workers.

  1998cited by this paper
• High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids.

  1995cited by this paper
• Comprehensive assay for pyrazinamide, rifampicin and isoniazid with its hydrazine metabolites in human plasma by column liquid chromatography.

  1994cited by this paper
• Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin.

  1986cited by this paper
• Plasma Hydrazine Concentrations in Man after Isoniazid and Hydralazine Administration

  1985cited by this paper
• Spin trapping of a free radical intermediate formed during microsomal metabolism of hydrazine.

  1985cited by this paper
• Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.

  1976cited by this paper

• Precision Medicine Strategies to Improve Isoniazid Therapy in Patients with Tuberculosis

  2024cites this paper
• Association of Cytochrome P450 2E1 and N-Acetyltransferase 2 Genotypes with Serum Isoniazid Level and Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Cross-Sectional Study

  2023cites this paper
• Genetic polymorphisms of pharmacogenomic VIP variants in the Hui population from Ningxia Province of China

  2023cites this paper
• Advancing tuberculosis management: the role of predictive, preventive, and personalized medicine

  2023cites this paper
• Role of Pharmacogenomics in Reducing the Risk of Drug-Related Iatrogenesis

  2022cites this paper
• Characteristics of N-acetyltransferase 2 Phenotype Status and Pharmacokinetic Parameters of Vietnam Pulmonary Tuberculosis Patients

  2022cites this paper
• Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS

  2022cites this paper
• Polymorphisms in drug metabolism genes as a risk factor for first-line anti-tuberculosis drug-induced liver injury

  2022cites this paper
• From dietary adaptation in the past to drug metabolism of today: An example of NAT genes in the Croatian Roma

  2022cites this paper
• Isoniazid: An Exploratory Review

  2022cites this paper
• Impact of DNA methylation on ADME gene expression, drug disposition, and efficacy

  2022cites this paper
• Special Section on Drug Metabolism in Liver Injury and Repair — Minireview Novel Clinical Biomarkers for Drug-Induced Liver Injury S

  2022cites this paper
• Novel Clinical Biomarkers for Drug-Induced Liver Injury

  2021cites this paper
• Transporter, Drug Metabolism, and Drug‐Induced Liver Injury in Marketed Drugs

  2021cites this paper
• PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid

  2021cites this paper
• Pharmacokinetics of isoniazid: The good, the bad, and the alternatives.

  2019cites this paper
• Pharmacokinetics of Isoniazid-induced Rhabdomyolysis in a Girl

  2018cites this paper
• The influence of acetylation status of tuberculosis patients on the isoniazid serum concentrations and sputum conversion after intensive phase therapy

  2018cites this paper
• Distribution of rs1801279 and rs1799930 Polymorphisms in NAT2 Gene among Population in Kupang, Nusa Tenggara Timur, Indonesia

  2018cites this paper
• IBL Conference 2017-Proceedings CYP 2 E 1 genotype and transaminase level of tuberculosis patients receiving fixed dose combination of antituberculosis I

  2017cites this paper
• Analysis of GSTM1 Deletion on Adult Pulmonary Tuberculosis Patients

  2017cites this paper
• Analysis of GSTM 1 Deletion on Adult Pulmonary Tuberculosis Patients

  2017cites this paper
• 3 Pharmacogenetics and Metabolism : Past , Present and Future

  2017cites this paper
• Effect of gene–gene and gene–environment interactions associated with antituberculosis drug-induced hepatotoxicity

  2017cites this paper
• Increasing serum transaminase is not associated with the serum isoniazid and rifampicin levels in tuberculosis patients treated with fixed-dose combination antituberculosis in Yogyakarta

  2017cites this paper
• Acetylator Status on Tuberculosis Patients Receiving Isoniazid-Contained Antituberculosis Regiment

  2017cites this paper
• Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation

  2017cites this paper
• N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study

  2016cites this paper
• Correlation of CpG Island Methylation of the Cytochrome P450 2E1/2D6 Genes with Liver Injury Induced by Anti-Tuberculosis Drugs: A Nested Case-Control Study

  2016cites this paper
• Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil.

  2016cites this paper
• Association of hydrazine and SGPT level two hours after drug administration at the end of intensive phase treatment of pulmonary tuberculosis patients

  2016cites this paper
• The effect of ageing on isoniazid pharmacokinetics and hepatotoxicity in Fischer 344 rats

  2016cites this paper
• CYP2E1 polymorphism, acetylator profiles and drug-induced liver injury incidence of Indonesian tuberculosis patients.

  2016cites this paper
• PharmGKB summary: isoniazid pathway, pharmacokinetics

  2016cites this paper
• Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines Part 2

  2016cites this paper
• A Case of Seizure and Metabolic Acidosis Due to Renal Adjustment Dosage of Isoniazid in an Elderly Woman

  2014cites this paper
• Genetic polymorphisms in metabolic enzymes and susceptibility to anti-tuberculosis drug-induced hepatic injury.

  2014cites this paper
• Improvements in algorithms for phenotype inference: the NAT2 example.

  2014cites this paper
• Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate

  2014cites this paper
• N‐acetyltransferase 2, cytochrome P4502E1 and glutathione S‐transferase genotypes in antitubercular treatment‐induced hepatotoxicity in North Indians

  2014influential citation
• Impact of food intake on the pharmacokinetics of first-line antituberculosis drugs in Taiwanese tuberculosis patients.

  2014cites this paper
• Isoniazid-induced liver injury and immune response in mice

  2014influential citation
• Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity.

  2014cites this paper
• PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

  2014cites this paper
• Relative bioavailability of isoniazid in a fixed-dose combination product in healthy Mexican subjects.

  2014cites this paper
• Major Human Conjugative Drug‐Metabolizing Enzymes

  2014cites this paper
• Investigation of the Mechanism of Idiosyncratic Drug-induced Liver Injury

  2014cites this paper
• Paradoxical Attenuation of Autoimmune Hepatitis by Oral Isoniazid in Wild-Type and N-Acetyltransferase–Deficient Mice

  2014cites this paper
• N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients.

  2013cites this paper
• Tuberculosis Pharmacogenetics: State of The Art

  2013cites this paper
• Clarifying haplotype ambiguity of NAT2 in multi-national cohorts.

  2013cites this paper
• Chapter 6 Tuberculosis Pharmacogenetics : State of The Art

  2013cites this paper
• Phenotypic interaction of simultaneously administered isoniazid and phenytoin in patients with tuberculous meningitis or tuberculoma having seizures.

  2013cites this paper
• Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapy.

  2013cites this paper
• Mechanism-based inhibition of CYP450: an indicator of drug-induced hepatotoxicity.

  2013cites this paper
• [Nutritional assessment upon admission for predicting delay in negative bacillary conversion among patients treated for pulmonary tuberculosis].

  2013cites this paper
• Conjugation, Transport, and Elimination of Drugs in Humans

  2012cites this paper
• Topics on Drug Metabolism

  2012cites this paper
• A study of genetic polymorphism underlying idiosyncratic hepatotoxicity due to anti-tuberculosis medications

  2012influential citation
• Pharmacogenetics and Metabolism: Past, Present and Future

  2012cites this paper
• Direct Oxidation and Covalent Binding of Isoniazid to Rodent Liver and Human Hepatic Microsomes: Humans Are More Like Mice than Rats

  2012cites this paper
• Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.

  2012cites this paper
• Genetic Interaction between NAT2, GSTM1, GSTT1, CYP2E1, and Environmental Factors Is Associated with Adverse Reactions to Anti-Tuberculosis Drugs

  2012cites this paper
• Pharmacogenetics in Drug Metabolism: Role of Phase I Enzymes

  2012cites this paper
• Hair Analysis for Determination of Isoniazid Concentrations and Acetylator Phenotype during Antituberculous Treatment

  2012cites this paper
• Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients.

  2011cites this paper
• Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.

  2011cites this paper
• Smoking and Polymorphisms in Xenobiotic Metabolism and DNA Repair Genes are Additive Risk Factors Affecting Bladder Cancer in Northern Tunisia

  2011cites this paper
• Pharmacokinetic properties of newly synthesized retinoid X receptor agonists possessing a 6-[N-ethyl-N-(3-alkoxy-4-isopropylphenyl)amino]nicotinic acid skeleton in rats

  2011cites this paper
• Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects

  2011cites this paper
• Chapter 18: Pharmacogenetics of Antituberculosis Drugs

  2011cites this paper
• Influence of genetic polymorphisms of xenobiotic metabolizing enzymes on the risk of developing leukemia in a Tunisian population.

  2011cites this paper
• Pharmacogenetics in reproductive and perinatal medicine.

  2010cites this paper
• Liver injury caused by drugs: an update.

  2010cites this paper
• Polimorfismos em CYP2E1, GSTM1 e GSTT1 e hepatotoxicidade no tratamento da tuberculose

  2010cites this paper
• N-acetyl transferase 2 polymorphisms associated with isoniazid pharmacodynamics: molecular features for ligand interaction.

  2010cites this paper
• Combined effect of NAT2, MTR and MTHFR genotypes and tobacco on bladder cancer susceptibility in Tunisian population.

  2009cites this paper
• Do smoking and polymorphisms in xenobiotic metabolizing enzymes affect the histological stage and grade of bladder tumors?

  2009cites this paper
• Pharmacokinetics and safety of single and multiple doses of Asacol tablets in Japanese healthy volunteers

  2009cites this paper
• Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population.

  2009cites this paper